Compare TREE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.5M | 467.8M |
| IPO Year | 2008 | 2019 |
| Metric | TREE | FULC |
|---|---|---|
| Price | $38.26 | $3.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $71.25 | $16.38 |
| AVG Volume (30 Days) | 204.1K | ★ 4.5M |
| Earning Date | 04-30-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 443.31 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,117,324,000.00 | N/A |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $30.11 | ★ N/A |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $32.65 | $2.83 |
| 52 Week High | $77.35 | $15.74 |
| Indicator | TREE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 34.08 |
| Support Level | $34.05 | $2.83 |
| Resistance Level | $40.00 | $8.34 |
| Average True Range (ATR) | 1.96 | 0.24 |
| MACD | 0.30 | 0.11 |
| Stochastic Oscillator | 69.79 | 61.49 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.